ミズーリ州における非小細胞肺癌の臨床試験
ミズーリ州内の拠点で、非小細胞肺癌に関する86件の研究が参加者を募集しています。
ミズーリ州内の都市
- St. Louis73件の研究
- Kansas City31件の研究
- Springfield10件の研究
- Cape Girardeau9件の研究
- Lee's Summit9件の研究
- O'Fallon8件の研究
- Columbia8件の研究
- Joplin4件の研究
- Saint Joseph3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Saint Francis Medical Center, Cape Girardeau
- Saint Luke's Hospital, Chesterfield
- 他18件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Saint Francis Medical Center, Cape Girardeau
- Parkland Health Center - Farmington, Farmington
- Sainte Genevieve County Memorial Hospital, Sainte Genevieve
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07293247A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Washington University Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Washington University School of Medicine ( Site 3279), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Saint Francis Medical Center, Cape Girardeau
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07388524Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- University Health Truman Medical Center, Kansas City
- Mercy Hospital South, St Louis
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Missouri Cancer Associates, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Missouri Cancer Associates, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Washington University Center for Advanced Medicine, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Washington University School of Medicine - Siteman Cancer Center, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Missouri Cancer Associates, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Washington University School Of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Mercy South - David M Sindelar Cancer Center ( Site 0098), St Louis
- Mercy Research - David C. Pratt Cancer Center ( Site 0006), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312137Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Washington University, St Louis
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Saint Luke's Hospital of Kansas City, Kansas City
- Saint Luke's East Hospital, Lee's Summit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Truman Medical Ctr West, Kansas City
- Oncology Hematology Associates, Springfield
- Washington University School Of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Washington University School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Washington University in St Louis, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667908A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Bridgeton
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Missouri Baptist Medical Center, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他18件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0498, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07140016A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
- Hulston Cancer Center /ID# 232226, Springfield
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT04928846Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Missouri Cancer Associates, Columbia
- SSM Health Cancer Care - St. Clare, Fenton
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Washington University School of Medicine, St Louis
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0685, Fenton
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06529822A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Bridgeton
- Research Site, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Kansas City
- Clinical Study Site, St Louis
- Clinical Study Site, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Washington University School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06855771Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。